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 
Abstract— While the benefits of glycemic control for critically ill patients are increasingly demonstrated, the ability to deliver safe, 
effective control to intermediate target ranges is widely debated due to the increased risk of hypoglycemia. This study analyzes 
interim clinical trial results of the fully computerized model-based Stochastic TARgeted (STAR) glycemic control framework at the 
University Hospital of Liège, Belgium. Patients with dysglycemia were randomly assigned to the full version of STAR, modulating 
both insulin and nutrition inputs, or STAR-IO, an insulin only version of STAR. Both arms target the normoglycemic 80-145 mg/dL 
(4.4-8.0 mmol/L) band. Results are further compared to retrospective data from 20 patients under the standard unit protocol 
targeting a higher 100-150 mg/dL (5.6-8.3 mmol/L) band. Much higher time in target band is provided under the full version of 
STAR, with similar safety and significantly lower incidence of mild hyperglycemia (blood glucose > 145 mg/dL or 8.0 mmol/L) and 
severe hyperglycemia (blood glucose > 180 mg/dL or 10.0 mmol/L). As a result, lower median blood glucose levels are safely and 
consistently achieved with lower glycemic variability, suggesting STAR’s potential to improve clinical outcomes. These interim 
results show the possibility to achieve safe, effective control for all patients using STAR, and suggest glycemic control to lower targets 
could be beneficial. 
I. INTRODUCTION 
Critically ill patients often experience hyperglycemia as a result of stress and inflammatory metabolic response to injury [1], 
which is associated with increased intensive care unit (ICU) morbidity and mortality [2]. Glycemic control (GC) using insulin 
therapy has improved patient outcomes, and reduced patient length of stay and clinical workload [3-6]. However, GC has been 
proven hard to achieve safely, leading to increased blood glucose (BG) variability and risk of hypoglycemia [7-9], also 
independently associated with increased morbidity and mortality [9-11]. As a result, the appropriate target band for glycemic 
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control has been widely debated [12, 13], with the fear of hypoglycemia from GC being potentially more harmful than beneficial 
for the patients [14].  
However, recent studies show model-based computerized GC methods successfully control BG to lower target bands without 
significantly increasing hypoglycemic risks [15, 16]. Such models use key physiological parameters and account for inter- and 
intra- patient variability [17-19]. Patient-specificity for GC solutions in ICUs have been shown essential for control quality and 
control [20]. Over the years, some critical factors have been identified for good protocol design, including safety, performance, 
compliance to protocol, and repeatability across units [16, 17, 21, 22]. More specifically, using a GC protocol design not 
providing these critical aspects can bias results [23]. 
The Stochastic TARgeted (STAR) GC framework uses physiological and stochastic models to uniquely dose both insulin 
and nutrition inputs [24, 25]. It identifies the patient-specific insulin sensitivity (SI) [26] and forecasts metabolic variability, 
offering a unique risk-based dosing approach accounting for inter- and intra- patient variability [24]. STAR is fully computerized, 
adjustable to different ICU practices, and has shown positive, near identical results in multiple centers, which no other protocol 
has done [16].  
This paper analyzes interim clinical trial results of STAR in a Belgian ICU. 
II. METHODS 
A. STAR-Liège Clinical Trial Design and Protocol 
The STAR-Liège clinical trial is designed to evaluate the STAR framework for GC at the University Hospital of Liège, 
Belgium. Previous studies on STAR have shown safe and effective control achieved for nearly all patients, while providing better 
nutrition than most ICUs in the world [16, 27]. This trial includes two arms. The first uses an insulin-only version of STAR 
(STAR-IO), while the second modulates both enteral nutrition and insulin inputs using STAR. In STAR-IO, nutrition is left at 
clinician discretion, while in STAR, the nutrition rate is derived from a daily base rate of 2000 kcal/day nutritional intake, and 
adapted for GC [27]. 
Starting criteria is 2 consecutive BG measurements > 150 mg/dL (8.0 mmol/L). BG assays are via either blood gas analyzer 
or standard glucometers. Insulin is administered continuously through intravenous catheter, with increments of maximum 2 U/h, 
and limited to a maximum infusion rate of 9U/h. Enteral nutrition can be adjusted treatment to treatment by maximum 30% of 
the original 100% goal feed (GF) rate, going no lower than 30% of the original GF. The target band is 80-145 mg/dL (4.4-8.0 
mmol/L). STAR is stopped either if the patient BG is stabilized for 6 hours (BG in target band and insulin ≤ 2 U/h) or after 72h 
  
of treatment. The protocol is implemented on Android tablets at the patient bedside. The University Hospital of Liège Ethics 
Committee approved this trial (#B707201733994) and the use of collected data. 
STAR uses patient clinical data to identify the patient-specific current SI level [26], using a clinically validated physiological 
model [28]. Potential future metabolic variability is then assessed based on this current SI level, using the stochastic model [25]. 
This probabilistic approach enables a forecast of the 5th-95th percentile range of likely future evolution of SI for the next 3 hours. 
Hence, a corresponding prediction of the 5th-95th percentile range for future BG evolution can be calculated for a given treatment. 
STAR thus determines the best insulin and nutritional interventions based on prediction of likely future BG that best overlaps 
the clinically chosen target band. Nutrition is reduced only if using insulin alone results in excessive predicted BG levels, giving 
a patient-specific indication of patient ability to tolerate glucose. STAR offers 1-3 hourly treatment options [16]. 
B. Protocol comparison analysis 
To date, 6 patients were included in the full STAR arm and 11 in STAR-IO. The study compares GC results with retrospective 
data from 20 patients under the standard protocol. The standard protocol is table-based, targeting a higher 100-150 mg/dL (5.6-
8.3 mmol/L) band, and BG measurements are typically taken 4-hourly [29]. Thus, it is expected to have slightly higher BG and 
lower workload. Statistics use hourly resampled BG. 
Safety is assessed by the %BG < 80 mg/dL (4.4 mmol/L), %BG < 72 mg/dL (4.0 mmol/L, or mild hypoglycemia), %BG < 
40 mg/dL (2.2 mmol/L, severe hypoglycemia), %BG  
TABLE I.  CLINICAL RESULTS SUMMARY FOR SAFETY, PERFORMANCE, AND COMPLIANCE TO PROTOCOL COMPARISON. 
 STAR STAR-IO Retro 
# Patients 6 11 20 
Total hours 308 645 5006 
Workload (meas/day) 12 16 7 







Median ΔBG (mg/dL) 5 [2, 9] 7 [4, 14] / 














% BG in 80-117 mg/dL 49.4 41.3 / 
% BG in 80-145 mg/dL 90.1 77.9 55.4 
% BG in 145-180 mg/dL 8.7 10.9 31.3 
  
 STAR STAR-IO Retro 
% BG > 180 mg/dL 0.3 9.8 12.0 
% BG < 80 mg/dL 1.0 1.4 1.3 
% BG < 72 mg/dL 1.0 0.5 0.5 
% BG < 40 mg/dL 0 0 0 
# Patients < 40 mg/dL 0 0 0 
% intervention changed 1.4 10.2 21.3 
% max option chosen 89.0 89.9 / 
Median max. option avail. 3 [1 3] 1 [1 2] / 
 
Data given as median [IQR] as appropriate, divide by 18 for mmol/L. 
in 145-180 mg/dL (8.0-10.0 mmol/L, or mild hyperglycemia), and %BG > 180 mg/dL (10.0 mmol/L, severe hyperglycemia). 
The number of patients experiencing severe hypoglycemia is also reported. Performance is evaluated by the median [interquartile 
range (IQR)] BG levels, and %BG in target band and the 80-117 mg/dL (4.4-6.5 mmol/L) intermediate range. Finally, protocol 
compliance is assessed by the number of interventions changed from the original recommendation. 
III. RESULTS 
Clinical results are presented in Table 1 and Figure 1. Per-patient BG traces over time are in Figure 2. 
STAR has lower, less variable, and tighter BG levels than STAR-IO (117 [108, 126] vs 121 [106, 139] mg/dL). The %BG 
in target band is significantly higher (90.1 vs 77.9%), and 8% more in the tighter 80-117 mg/dL range. High, similar safety is 
achieved for both STAR and STAR-IO, with less than 1.4% of BG below target band and no severe hypoglycemia. While %BG 
in mild hyperglycemia is similar (~10%), the %BG in severe hyperglycemia is significantly higher for STAR-IO (0.3% vs 9.8%). 
Compliance to protocol is higher for STAR, with only 1.4% of interventions changed compared to 10.2% with STAR-IO. 
Nurses picked the maximum measurement interval option 90% of the time for both arms. These numbers are also reflected in 
the lower workload demand for STAR (12 vs 16 measurements per day). Median insulin infusion rates were similar for both 
arms (3.5 [2.5, 4.5] vs 3.5 [1.5, 6.0] U/h), but less variable for STAR. Finally, nutrition intake is slightly higher for STAR-IO 




Figure 1.  Cohort resampled BG, inuslin rate, and glucose rate cumulative distribution functions. Overall, BG achieved is lower and less variable (top) for 
STAR (blue) compared to STAR-IO (green), with lower insulin (middle) and nutrition (bottom) rates. 
 
Figure 2.  Patients BG traces evolution over time. Green lines show patients under the STAR-IO protocol and blue lines show patients under the full STAR 
protocol. Black dashed lines represent the target band. 
The retrospective cohort median BG was higher (139 [117, 160] mg/dL), likely explained by the higher target band with lower 
insulin rates administered than STAR (2.5 [2.0, 3.0] U/h). Safety is comparable to STAR in terms of hypoglycemia, but there is 
much higher %BG in mild and severe hyperglycemic ranges (31.1% and 12.0% respectively). This result could also be explained 
by the higher nutrition rates (9.8 [8.6, 11.5] g/h). Workload is much lower (7 measurements per day), but protocol compliance 
is lower, with up to 21.3% of interventions changed.  
  
Overall, the full version of STAR achieved safer, more effective control with high nutrition intake and lower workload than 
STAR-IO. The high compliance to protocol suggests the STAR framework to be adopted. 
IV. DISCUSSION 
While STAR-IO shows high safety and performance compared to the standard protocol, the full version of STAR clearly 
achieves better glycemic control outcomes through modulation of nutrition in addition to insulin. Typically, STAR better controls 
more resistant patients by slightly lowering carbohydrate intake to safely bring BG into the safe target band, where STAR-IO 
will fail to control their persistent hyperglycemia in the same case. This key difference has a direct impact on both the increased 
time in target band and lower workload. This unique risk-based dosing approach, controlling both inputs, also reduces glycemic 
variability. Most importantly, despite controlling nutrition, STAR has been shown to provide better caloric intake than most ICU 
in the world [27]. 
Starting BG are higher in patients receiving GC under STAR-IO, as shown in Figure 2. This may contribute to the higher 
%BG > 180 mg/dL. However, Figure 2 shows STAR is also much more effective at maintaining BG in the target range once it 
is inside. This improved performance is likely due to feed modulation, where persistent hyperglycemia is treated with feed 
reductions in addition to insulin. A case study is shown in Figure 3, where glucose-insulin interventions and outcomes are shown 
for a patient on STAR and another on STAR-IO. In Patient A, on STAR, feed is first increased to 100% GF then reduced to 
~30% after 6 hours of GC. Underlying SI allows STAR to reduce nutrition rates where it will not be tolerated, as would be 
indicated by persistent hyperglycemia. Hence, this temporary lower dextrose rate is safer for the patient. By hour 31, nutrition 
rate is progressively increased back to 100% GF as the patient metabolism is better able to handle higher dextrose intake. In 
contrast, Patient B nutrition rate is kept constant (as per clinical guidelines), resulting in consistent high BG levels, above, or 
close to the upper target band limit, with higher associated insulin rates. This may often lead to hypoglycemia and higher 
glycemic variability if patient SI changes due to underlying condition, or other clinical interactions. 
The small number of patients included to date may impact the results. Only 6 patients were in the full STAR protocol and 11 
in STAR-IO. However, these patients come from the same ICU population, and are reflective of the general population with 
similar median [IQR] identified SI levels for both groups (3.4x10-4 [2.7x10-4, 4.2x10-4] for STAR vs 3.5x10-4 [2.5x10-4, 5.8x10-
4] L/mU/min for STAR-IO). 
The difference in protocol compliance could be explained by two main factors. First, the first patients were included in the 
STAR-IO protocol. The STAR framework was new to clinical staff, and potentially induced a fear of change and, thus, the 
greater (10%) interventions changed handled control. Second, the lower target band used by STAR may have affected clinical 
  
staff fear of hypoglycemia. In contrast, the 1.4% interventions changed in the full STAR arm were only modifications due to 
conflict with ICU guidelines limiting the maximum increase in nutrition rate. 
Although the retrospective protocol target band is clearly higher than STAR (100-150 mg/dL), risks of hypoglycemia are 
similar. However, the %BG above 145 mg/dL and the severe hyperglycemic threshold of 180 mg/dL are also much higher. 
Additionally, the %BG in band for this protocol is only 54% compared to 77-90% for STAR. This is achieved with much lower 
workload (7 vs 12 measurements per day), 
 
 
Figure 3.  BG levels, insulin rate, and nutrition rate for Patient A (top) on STAR, and Patient B (bottom) on STAR-IO. Dashed line shows the 80-145 
mg/dL target band. 
reflecting the big tradeoff of measurement frequency to achieve high control quality, where too low a frequency can increase 
hypoglycemic risks and lower time in band, while too high a frequency leads to excessive clinical burden. The resulting median 
[IQR] BG is much higher than STAR, with 25% of BG measurements higher than 160 mg/dL. Finally, while being the standard 
of care in this ICU, more than 20% of interventions are changed by clinical staff, leading to important influence from clinical 
judgment on GC outcomes, hence questioning results and protocol design. 
This analysis shows model-based computerized methods using key physiological parameters can result in safe and effective 
GC, while targeting lower intermediate glycemic ranges, which are associated with improved outcomes [3, 30, 31]. Hence, it 
also suggests future larger studies comparing GC results and clinical outcomes should ensure they can provide very similar 
control quality in both arms before assessing potential benefits or making any conclusions. 
V. CONCLUSION 
In this clinical trial, STAR achieved safe and effective GC, with an encouraging high %BG in target band, and similar 
nutritional intake than clinically set (STAR-IO). This high control quality was achieved with similar safety than the standard 
protocol targeting higher ranges. Thus, STAR provides safe and effective control to a lower 80-145 mg/dL target band, for all 
patients in this unit, as it has in others internationally. These promising results suggest the continuation of the trial. 
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